Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560438093> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2560438093 abstract "336 Background: Bevacizumab is a humanized monoclonal antibody directed against the VEGF ligand. Clinical trials with this drug mainly included patients with renal cell cancer (in combination with interferon-alpha) and several other solid tumors (in combination with cytotoxic chemotherapy). Although hematologic toxicities are not among the main concerns associated with the addition of bevacizumab, discontinuation of therapy or dose reductions due to these toxicities have been reported. We performed a meta-analysis to determine the incidence and risk of hematologic toxicities associated with bevacizumab use. Methods: The databases of Medline were searched for articles from 1966 to September 2010. Abstracts presented at the American Society of Clinical Oncology meetings were also searched. Eligible studies include randomized trials with bevacizumab, and adequate safety data profile reporting anemia, neutropenia, febrile neutropenia, or thrombocytopenia. Statistical analyses were conducted to calculate the summary incidence, RR, and 95% confidence intervals (CI). Results: A total of 15,239 patients were included in the analysis. The incidence of bevacizumab-associated all-grade anemia, neutropenia and thrombocytopenia were 19.4%, 22.3%, and 14.5%, respectively. The incidences of high-grade events were 3.94%, 18.4% and 3.38%, respectively. Febrile neutropenia was present in 3.75% of patients. Bevacizumab was associated with a decreased risk of high-grade anemia (RR=0.73; 95% CI 0.60-0.89; p=0.002), and increased risks of high-grade neutropenia (RR=1.08; 95% CI 1.02-1.13; p=0.005) and febrile neutropenia (RR=1.31; 95% CI 1.08-1.58; p=0.006), as compared to the non-bevacizumab containing arms. Stratified analysis by the dose of bevacizumab (2.5mg/wk vs. 5mg/wk) demonstrated similar risks. Conclusions: Concurrent use of bevacizumab with chemotherapy or immunotherapy is associated with a lower risk of high-grade anemia and an increased risk of high-grade neutropenia and febrile neutropenia. [Table: see text]" @default.
- W2560438093 created "2016-12-16" @default.
- W2560438093 creator A5018055906 @default.
- W2560438093 creator A5021572863 @default.
- W2560438093 creator A5052504518 @default.
- W2560438093 creator A5091352250 @default.
- W2560438093 date "2011-03-01" @default.
- W2560438093 modified "2023-09-24" @default.
- W2560438093 title "Hematologic toxicities in renal cell carcinoma and other malignancies treated with bevacizumab: A meta-analysis of clinical trials." @default.
- W2560438093 doi "https://doi.org/10.1200/jco.2011.29.7_suppl.336" @default.
- W2560438093 hasPublicationYear "2011" @default.
- W2560438093 type Work @default.
- W2560438093 sameAs 2560438093 @default.
- W2560438093 citedByCount "0" @default.
- W2560438093 crossrefType "journal-article" @default.
- W2560438093 hasAuthorship W2560438093A5018055906 @default.
- W2560438093 hasAuthorship W2560438093A5021572863 @default.
- W2560438093 hasAuthorship W2560438093A5052504518 @default.
- W2560438093 hasAuthorship W2560438093A5091352250 @default.
- W2560438093 hasConcept C126322002 @default.
- W2560438093 hasConcept C143998085 @default.
- W2560438093 hasConcept C2776694085 @default.
- W2560438093 hasConcept C2777063308 @default.
- W2560438093 hasConcept C2777472916 @default.
- W2560438093 hasConcept C2777802072 @default.
- W2560438093 hasConcept C2778248108 @default.
- W2560438093 hasConcept C2778715236 @default.
- W2560438093 hasConcept C535046627 @default.
- W2560438093 hasConcept C71924100 @default.
- W2560438093 hasConcept C95190672 @default.
- W2560438093 hasConceptScore W2560438093C126322002 @default.
- W2560438093 hasConceptScore W2560438093C143998085 @default.
- W2560438093 hasConceptScore W2560438093C2776694085 @default.
- W2560438093 hasConceptScore W2560438093C2777063308 @default.
- W2560438093 hasConceptScore W2560438093C2777472916 @default.
- W2560438093 hasConceptScore W2560438093C2777802072 @default.
- W2560438093 hasConceptScore W2560438093C2778248108 @default.
- W2560438093 hasConceptScore W2560438093C2778715236 @default.
- W2560438093 hasConceptScore W2560438093C535046627 @default.
- W2560438093 hasConceptScore W2560438093C71924100 @default.
- W2560438093 hasConceptScore W2560438093C95190672 @default.
- W2560438093 hasLocation W25604380931 @default.
- W2560438093 hasOpenAccess W2560438093 @default.
- W2560438093 hasPrimaryLocation W25604380931 @default.
- W2560438093 hasRelatedWork W1872181102 @default.
- W2560438093 hasRelatedWork W1991469761 @default.
- W2560438093 hasRelatedWork W2102147859 @default.
- W2560438093 hasRelatedWork W2107675170 @default.
- W2560438093 hasRelatedWork W2151468115 @default.
- W2560438093 hasRelatedWork W2153892587 @default.
- W2560438093 hasRelatedWork W2162731664 @default.
- W2560438093 hasRelatedWork W2171762826 @default.
- W2560438093 hasRelatedWork W2590044683 @default.
- W2560438093 hasRelatedWork W2604085925 @default.
- W2560438093 hasRelatedWork W2733391944 @default.
- W2560438093 hasRelatedWork W2761059676 @default.
- W2560438093 hasRelatedWork W2770624431 @default.
- W2560438093 hasRelatedWork W2799391417 @default.
- W2560438093 hasRelatedWork W2806258060 @default.
- W2560438093 hasRelatedWork W2907555559 @default.
- W2560438093 hasRelatedWork W3096992798 @default.
- W2560438093 hasRelatedWork W656206267 @default.
- W2560438093 hasRelatedWork W2189459106 @default.
- W2560438093 hasRelatedWork W2618131231 @default.
- W2560438093 isParatext "false" @default.
- W2560438093 isRetracted "false" @default.
- W2560438093 magId "2560438093" @default.
- W2560438093 workType "article" @default.